These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 32057905

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms.
    Verwei M, Minekus M, Zeijdner E, Schilderink R, Havenaar R.
    Int J Pharm; 2016 Feb 10; 498(1-2):178-86. PubMed ID: 26688035
    [Abstract] [Full Text] [Related]

  • 3. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ, Pepin X, Markopoulos C, Vertzoni M, Reppas C, Dressman JB.
    Eur J Pharm Sci; 2017 May 01; 102():284-298. PubMed ID: 28286289
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S, Kambayashi A, Kojima H, Oku N, Asai T.
    Biol Pharm Bull; 2018 May 01; 41(11):1708-1715. PubMed ID: 30381671
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dissolution Profiles of Immediate Release Products of Various Drugs in Biorelevant Bicarbonate Buffer: Comparison with Compendial Phosphate Buffer.
    Okamoto N, Higashino M, Yamamoto H, Sugano K.
    Pharm Res; 2024 May 01; 41(5):959-966. PubMed ID: 38653942
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.
    O'Dwyer PJ, Box KJ, Imanidis G, Vertzoni M, Reppas C.
    Eur J Pharm Sci; 2022 Jan 01; 168():106034. PubMed ID: 34628003
    [Abstract] [Full Text] [Related]

  • 10. Dissolution profiles of BCS class II drugs generated by the gastrointestinal simulator alpha has an edge over the compendial USP II method.
    Naing MD, Tsume Y.
    Eur J Pharm Biopharm; 2024 Oct 01; 203():114436. PubMed ID: 39111581
    [Abstract] [Full Text] [Related]

  • 11. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E, De Maio V, Ronda E, Mattavelli V, Vertzoni M, Dressman JB.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):434-41. PubMed ID: 19491035
    [Abstract] [Full Text] [Related]

  • 12. New Approach for the Application of USP Apparatus 3 in Dissolution Tests: Case Studies of Three Antihypertensive Immediate-Release Tablets.
    Espíndola B, Bortolon FF, Pinto JMO, Pezzini BR, Stulzer HK.
    AAPS PharmSciTech; 2018 Oct 28; 19(7):2866-2874. PubMed ID: 29934804
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F, Holm P, Larsen F, Steffansen B.
    Int J Pharm; 2014 Jan 30; 461(1-2):419-26. PubMed ID: 24342711
    [Abstract] [Full Text] [Related]

  • 15. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH, Shin S, Bulitta JB, Youn YS, Yoo SD, Shin BS.
    Mol Pharm; 2017 Jan 03; 14(1):53-65. PubMed ID: 27809538
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs.
    Georgaka D, Butler J, Kesisoglou F, Reppas C, Vertzoni M.
    Mol Pharm; 2017 Dec 04; 14(12):4181-4191. PubMed ID: 28366005
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An understanding of modified release matrix tablets behavior during drug dissolution as the key for prediction of pharmaceutical product performance - case study of multimodal characterization of quetiapine fumarate tablets.
    Kulinowski P, Woyna-Orlewicz K, Rappen GM, Haznar-Garbacz D, Węglarz WP, Dorożyński PP.
    Int J Pharm; 2015 Apr 30; 484(1-2):235-45. PubMed ID: 25701626
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
    Ali J, Zgair A, Hameed GS, Garnett MC, Roberts CJ, Burley JC, Gershkovich P.
    Int J Pharm; 2019 Jan 30; 555():228-236. PubMed ID: 30465852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.